Connor, Clark & Lunn Investment Management Ltd. Annexon, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024
BUY
$4.03 - $7.81 $213,372 - $413,508
52,946 Added 60.1%
141,037 $1.01 Million
Q4 2023

Feb 09, 2024
SELL
$1.63 - $4.63 $54,277 - $154,174
-33,299 Reduced 27.43%
88,091 $399,000
Q3 2023

Nov 13, 2023
SELL
$2.13 - $3.84 $43,309 - $78,078
-20,333 Reduced 14.35%
121,390 $286,000
Q2 2023

Aug 10, 2023
BUY
$2.1 - $6.37 $170,146 - $516,110
81,022 Added 133.48%
141,723 $498,000
Q1 2023

May 09, 2023
BUY
$3.74 - $7.46 $227,021 - $452,829
60,701 New
60,701 $233,000

Others Institutions Holding ANNX

# of Institutions
158
Shares Held
102M
Call Options Held
3.61M
Put Options Held
1.08M
View Full List

About Annexon, Inc.

ANNX Quotes by TradingView
  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $312M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email